What are the benefits and risks of natalizumab for adults with secondary progressive multiple sclerosis (SPMS)?

Cochrane Clinical Answers 2026

View at publisher

Authors: Aileen A. Antonio‐Santos

DOI: 10.1002/cca.4699

Cited by: 0

References: 1

Fields of Study & Subjects

Multiple Sclerosis Research Studies Psoriasis: Treatment and Pathogenesis Inflammatory Bowel Disease

References 1